751 results on '"Peggs, Karl S"'
Search Results
2. Author Correction: The evolution of lung cancer and impact of subclonal selection in TRACERx
3. The evolution of non-small cell lung cancer metastases in TRACERx
4. The evolution of lung cancer and impact of subclonal selection in TRACERx
5. Anti-CTLA-4 antibodies drive myeloid activation and reprogram the tumor microenvironment through FcγR engagement and type I interferon signaling
6. Dual targeting of CD19 and CD22 with bicistronic CAR-T cells in patients with relapsed/refractory large B-cell lymphoma
7. Donor whole blood DNA methylation is not a strong predictor of acute graft versus host disease in unrelated donor allogeneic haematopoietic cell transplantation
8. Multinational Study Assessing Treatment Patterns, Outcomes, and Healthcare Resource Utilization in Hematopoietic Stem Cell Transplant Recipients with Cytomegalovirus Infection and Intolerance to Anti-Cytomegalovirus Therapies
9. Cytotoxic T Cells for Infections: From Donor Specific to 'Off the Shelf'
10. Author Correction: Anti-CTLA-4 antibodies drive myeloid activation and reprogram the tumor microenvironment through FcγR engagement and type I interferon signaling
11. Fcγ receptors and immunomodulatory antibodies in cancer
12. CD25-Treg-depleting antibodies preserving IL-2 signaling on effector T cells enhance effector activation and antitumor immunity
13. Allo-HSCT in transplant-naïve patients with Hodgkin lymphoma: a single-arm, multicenter study
14. The T cell differentiation landscape is shaped by tumour mutations in lung cancer
15. Treatment for First Cytomegalovirus Infection Post–Hematopoietic Cell Transplant in the AURORA Trial: A Multicenter, Double-Blind, Randomized, Phase 3 Trial Comparing Maribavir With Valganciclovir.
16. AKT inhibition generates potent polyfunctional clinical grade AUTO1 CAR T-cells, enhancing function and survival
17. Impact of baseline and week 2 and week 4 post-transplant CMV cell-mediated immunity on risk of CMV infections and mortality in allogeneic hematopoietic cell transplant recipients
18. Evolving adoptive cellular therapies in urological malignancies
19. Impact of Alemtuzumab Scheduling on Graft-versus-Host Disease after Unrelated Donor Fludarabine and Melphalan Allografts
20. Natural History of Epstein-Barr Virus Replication and Viral Load Dynamics after Alemtuzumab-Based Allogeneic Stem Cell Transplantation
21. Off-the-shelf EBV-specific T-cell Immunotherapy for EBV-associated PTLD
22. Cytotoxic T Cells for Infections: From Donor Specific to “Off the Shelf”
23. Long-term outcome analysis of reduced-intensity allogeneic stem cell transplantation in patients with mantle cell lymphoma: a retrospective study from the EBMT Lymphoma Working Party
24. Targeting the T cell receptor [beta]-chain constant region for immunotherapy of T cell malignancies
25. Supplemental Figure Legends from TALEN-Mediated Inactivation of PD-1 in Tumor-Reactive Lymphocytes Promotes Intratumoral T-cell Persistence and Rejection of Established Tumors
26. Data from TALEN-Mediated Inactivation of PD-1 in Tumor-Reactive Lymphocytes Promotes Intratumoral T-cell Persistence and Rejection of Established Tumors
27. Supplemental Figures from TALEN-Mediated Inactivation of PD-1 in Tumor-Reactive Lymphocytes Promotes Intratumoral T-cell Persistence and Rejection of Established Tumors
28. A novel predictive algorithm to personalize autologous T-cell harvest for chimeric antigen receptor T-cell manufacture
29. Long-Term Follow-up of AUTO1, a Fast-Off Rate CD19 CAR, in Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia and Factors Associated with Durable Response
30. Impact of Pretransplantation 18F-Fluorodeoxyglucose-Positron Emission Tomography on Survival Outcomes after T Cell–Depleted Allogeneic Transplantation for Hodgkin Lymphoma
31. Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade
32. Body composition and lung cancer-associated cachexia in TRACERx
33. The evolution of lung cancer and impact of subclonal selection in TRACERx
34. Evolutionary characterization of lung adenocarcinoma morphology in TRACERx
35. TALEN-mediated genetic inactivation of the glucocorticoid receptor in cytomegalovirus-specific T cells
36. Impact of Baseline and Week 2 and Week 4 Posttransplant CMV Cell-Mediated Immunity on Risk of CMV Infections and Mortality in Recipients of Allogeneic Hematopoietic Cell Transplant.
37. Immunotherapy with CD25/CD71-allodepleted T cells to improve T-cell reconstitution after matched unrelated donor hematopoietic stem cell transplant: a randomized trial
38. Reprint of: Recent Advances in Cytomegalovirus: An Update on Pharmacologic and Cellular Therapies
39. CMV promotes recipient T-cell immunity following reduced-intensity T-cell–depleted HSCT, significantly modulating chimerism status
40. Recent Advances in Cytomegalovirus: An Update on Pharmacologic and Cellular Therapies
41. Safety, Efficiency and Long-Term Follow-up of AUTO1, a Fast-Off Rate CD19 CAR in Relapsed/Refractory B-Cell Acute Lymphoblastic Leukaemia and Other B-Cell Malignancies
42. Immunotherapy for transplantation-associated viral infections
43. Phylogenetic ctDNA analysis depicts early-stage lung cancer evolution
44. Impact of tumour microenvironment and Fc receptors on the activity of immunomodulatory antibodies
45. Molecular remission of infant B-ALL after infusion of universal TALEN gene-edited CAR T cells
46. Clinical Implications of Immune Reconstitution Following Hematopoietic Stem Cell Transplantation
47. Checkpoint Blockade and Combinatorial Immunotherapies
48. Tumour heterogeneity and immune-modulation
49. Human herpesvirus 6 and CAR T-cell toxicity
50. The role of virus-specific adoptive T-cell therapy in hematopoietic transplantation
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.